March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR ...
Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...
FDA Grants Orphan Drug Designation to March Biosciences for T-Cell Lymphoma
By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T ...
Pharmabiz9 天
March Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed ...
Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...
Morningstar11 天
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR ...
HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases ...
manilatimes11 天
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR ...
HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today ...
Castle Biosciences director sells $221,636 in stock
Daniel Bradbury, a director at Castle Biosciences Inc . (NASDAQ:CSTL), recently sold shares in the company totaling $221,636. The transactions, which took place on February 5, involved the sale of ...
Taiwan News3 天
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following ...